The AAN Annual Meeting connects vibrant communities of neurologists and neuroscience professional from around the world in-person and online. “The conference offers a robust lineup of diverse learning opportunities covering nearly every topic and subspecialty, helping members stay up to date on the latest trusted science and essential education.”
2025 has been a stellar year for Lange Neurology, PC. As we close the year, we continue to provide our patients with the highest standard...
Cartesian Therapeutics, Inc. has chosen Lange Neurology, PC as a trial site for its Phase III study of Descates-08 in patients with generalized myasthenia gravis...
Lange Neurology, PC has been designated a trial site by Immunovant, Inc. for its Phase IIb study of IMVT-1402 treatment in adults. Immunovant, Inc. is...
PhenoNet, a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders, has chosen Lange Neurology as...
Immunovant, Inc., a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases, has designated Lange Neurology PC, as a trial site...
Dr. Dale J. Lange attended the 36th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND) held December 5-7 in San Diego, CA.
Dr. Dale, J. Lange and research coordinators, Samantha Heffernan, FNP-BC, RN and Shannon Stevens, RN, CNRN attended 2025 Annual NEALS Meeting in Clearwater, Florida held...
Lange Neurology is currently recruiting patients of all genders, ages 18 – 100 who have been diagnosed with ALS within the past two years.
Dr. Dale J. Lange, a dual board-certified neurologist with a stellar reputation in the field of neurology, has unveiled Lange Neurology, PC in the heart...
